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Cyclooxygenase-2High-level expression of vascular endothelial growth factor (VEGF)-C is associatedwith chemoresistance and ad-
verse prognosis in acute myeloid leukemia (AML). Our previous study has found that VEGF-C induces
cyclooxygenase-2 (COX-2) expression in AML cell lines and signiﬁcant correlation of VEGF-C and COX-2 in
bone marrow specimens. COX-2 has been reported to mediate the proliferation and drug resistance in several
solid tumors. Herein,we demonstrated that theVEGF-C-induced proliferation of AML cells is effectively abolished
by the depletion or inhibition of COX-2. The expression of endothelin-1 (ET-1) rapidly increased following treat-
ment with VEGF-C.We found that ET-1was also involved in the VEGF-C-mediated proliferation of AML cells, and
that recombinant ET-1 induced COX-2 mRNA and protein expressions in AML cells. Treatment with the
endothelin receptor A (ETRA) antagonist, BQ 123, or ET-1 shRNAs inhibited VEGF-C-induced COX-2 expression.
Flow cytometry and immunoblotting revealed that VEGF-C induces S phase accumulation through the inhibition
of p27 and the upregulation of cyclin E and cyclin-dependent kinase-2 expressions. The cell-cycle-related effects
of VEGF-C were reversed by the depletion of COX-2 or ET-1. The depletion of COX-2 or ET-1 also suppressed
VEGF-C-induced increases in the bcl-2/bax ratio and chemoresistance against etoposide and cytosine arabinoside
in AML cells. We also demonstrated VEGF-C/ET-1/COX-2 axis-mediated chemoresistance in an AML xenograft
mouse model. Our ﬁndings suggest that VEGF-C induces COX-2-mediated resistance to chemotherapy through
the induction of ET-1 expression. Acting as a key regulator in the VEGF-C/COX-2 axis, ET-1 represents a potential
target for ameliorating resistance to chemotherapy in AML patients.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The role of angiogenic and lymphangiogenic growth factors in he-
matological malignancies and possible therapeutic applications of
each has been described [1]. Vascular endothelial growth factor-C
(VEGF-C) is a lymphangiogenic and angiogenic growth factor thatcyclin-dependent kinase; CKIs,
se; ET-1, endothelin-1; ETRA,
-C, vascular endothelial growth
ical Medicine, Taipei Medical
el.: +886 2 27361661x3237;
n).
ights reserved.signals through the VEGFR-3 (FLT-4) and VEGFR-2 (KDR) receptors
[2–5]. The VEGF-C signaling axis contributes to the progression of
solid tumors [6–8]. Acute myeloid leukemia (AML) is a malignancy
of the bone marrow with an overall long-term disease-free survival
of less than 50% [9]. The VEGF-C and VEGFR-3 proteins are expressed
in AML cell lines and primary AML cells [10,11]. Bone marrow biopsy
specimens from AML patients have been shown to contain higher
levels of VEGF-C and VEGFR-3 than normal volunteers [11,12]. The
VEGF-C/VEGFR-3 signaling axis in leukemia contributes to bonemarrow
neoangiogenesis andmetastasis [13]. In addition to tumor cells, stromal
cells can also secrete VEGF-C [14,15]. The expression of VEGF-C from
both leukemia and endothelial cells promotes leukemia cell survival
and proliferation through VEGFR-3-mediated pathways [10]. The ex-
pression of VEGF-C is a predictor of clinical outcome in both pediatric
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the importance of VEGF-C as a prognostic factor and potential therapeu-
tic target for the treatment of AML.
Resistance to chemotherapy and disease relapse remains signiﬁcant
clinical problems in AML. The identiﬁcation of genes and biological
pathways responsible for chemoresistance is therefore crucial for the
development of novel therapeutic approaches to improve patient
survival. The level of VEGF-C expression is also higher in patients
that take a longer time to reach complete remission after receiving
chemotherapy. In one previous study, endogenous VEGF-C levels signif-
icantly correlatedwith drug-resistance in primary AML cells of pediatric
patients [17], and VEGF-C expressed by bone marrow endothelial
cells has been shown to protect VEGFR-3-expressing AML cells
from chemotherapy-induced apoptosis [10]. The VEGF-C-mediated
protectionmay be the result of increased Bcl-2/Bax ratios [10]. Although
the importance of the VEGF-C/VEGFR-3 axis in bonemarrow angiogen-
esis, leukemic cell proliferation, and chemoresistance in AML are well
recognized, the molecular mechanisms underlying VEGF-C-mediated
survival and the effects of Bcl-2 induction in AML remain largely
unclear.
The effects of VEGF-C occur through its interaction with VEGFR-3
and downstream signaling. Upon VEGF-C binding, VEGFR-3 forms a
homodimer or heterodimer with VEGFR-2. Dimerization is followed
by autophosphorylation of the kinase domain and subsequent phos-
phatidylinositol 3-kinase-dependent Akt activation and protein
kinase C-dependent activation of the mitogen-activated protein
kinase (MAPK) pathways [18]. The VEGF-C/VEGFR-3 signaling up-
regulates genes involved in cell proliferation, survival, and metasta-
sis [8,10,17]. We have previously shown that VEGF-C activates pro-
angiogenic processes in the AML cell line, THP-1, by inducing
cyclooxygenase-2 (COX-2) expression. The expression of VEGF-C
also correlates with COX-2 protein levels in the bone marrow of
AML patients. We conﬁrmed the involvement of the JNK/AP-1 axis
in VEGF-C-dependent COX-2 expression [13]. Although peak VEGF-
C-dependent JNK activation was observed at 4 h, the duration of
COX-2 activation was more than 48 h. However, whether COX-2 is
directly induced by VEGF-C or a secondary signaling pathway is un-
known. In our current study, we identiﬁed endothelin-1 (ET-1) as a
key downstream target in the VEGF-C/VEGFR-3 axis-mediated regu-
lation of COX-2 expression, and determined the role of VEGF-C/ET-1/
COX-2 signaling in cell-cycle progression and chemoresistance in
AML cells.
2. Experimental procedures
2.1. Cell lines and reagents
The HL-60, U937, and THP-1 leukemic cell lines, each representing a
different type of acute myeloid leukemia, A549 and H928 lung adeno-
carcinoma cell lines, and MDA-MB-231 breast cancer cell line were
purchased from American Type Culture Collection (Manassas, VA,
USA). Leukemic cell lines, A549 and H928, were cultured in RPMI
1640 medium. MDA-MB-231 was cultured in DMEM/F12 medium.
Both media were supplemented with 10% heat-inactivated Gibco fetal
bovine serum (FBS; Invitrogen, Carlsbad, CA, USA), 2 mM L-glutamine,
100 U/mL penicillin, and 100 μg/mL streptomycin. The VEGF-C and
ET-1 were purchased from R&D Systems (Minneapolis, MN, USA)
and Bachem (Bubendorf, Switzerland), respectively. Other reagents,
including NS 398, BQ 123, BQ 788, etoposide, and cytosine arabinoside
(Ara-c), were purchased from Sigma-Aldrich (St Louis, MO, USA).
2.2. VEGF-C gene cloning
The VEGF-C complementary DNA (cDNA) was synthesized from
mRNA extracted from A549 cells. The oligonucleotide primers used
for the VEGF-C cloning were based on previously reported humansequence data (GenBank accession no. NM_005429). The sense and an-
tisense primers were 5′-ACGGATCCACTAGTATGCACTTGCTGGGCTTC-3′
and 5′-ACACGCGTCCTGCAGGTTAGCTCATTTGTGGTCTTTT-3′, respec-
tively. These primers were used in a reverse transcription (RT)-poly-
merase chain reaction (PCR) to produce the VEGF-C cDNA. The PCR
product of the expected sizewas puriﬁedusing theQIAquickGel Extrac-
tion Kit (Qiagen, Chatsworth, CA, USA), and digested with Bam HI and
Mlu I restriction enzymes (New England Biolabs, Beverly, MA, USA).
The digested product was ligated into the pWPI lentiviral vector
(Addgene, Cambridge, MA, USA) and sequenced.
2.3. Lentivirus production
The lentiviral envelope vector, pMD.G, and packaging vector,
pCMVΔR8.91, were purchased from the National RNAi Core Facility
at the Academic Sinica in Taipei, Taiwan, and transfected into 293T
packaging cells by calcium phosphate transfection. The 293T cells
(1 × 106) were seeded in 10-cm2 culture dishes one day before
transfection. The cells were transfected using a mixture of pWPI-
VEGF-C and pCMVΔR8.91 (10 μg each) and 1 μg of pMD.G. After a
5-h incubation, the transfection medium was replaced with fresh
culture medium. At 48 h post-transfection, the lentivirus containing
media was collected and centrifuged at 1500 rpm for 5 min to pellet
the cellular debris. The supernatant was ﬁltered through a 0.45-μm
ﬁlter, and stored at −70 °C. The pLKO.1/shET-1 and pLKO.1/shCOX-2
expression plasmids were also obtained from National RNAi Core Facil-
ity, and lentivirus production was performed as described above. The
target sequence of the VEGF-C shRNA-1 was 5′-CGC GAC AAA CAC
CTT CTT TAA-3′, the target sequence of the VEGF-C shRNA-2 was 5′-
CCC ACA AAG AAC TAG ACA GAA-3′, and the target sequence of the
VEGF-C shRNA-3was CCAACCGAGAAT TTGATGAAA-3′. The target se-
quence of the ET-1 shRNA-1 was 5′-AGA CAA ACA TGC AAG TAA AGA-
3′, and the target sequence of the ET-1 shRNA-2 was 5′-GCA GTT AGT
GAG AGG AAG AAA-3′. The target sequence of the COX-2 shRNA-1
was 5′-CCT GAA TTT AAC ACC CTC TAT-3′, and the target sequence of
the COX-2 shRNA-2 was 5′-CCA TTC TCC TTG AAA GGA CTT-3′. The tar-
get sequence of the scrambled shRNA was 5′-CCT AAG GTT AAG TCG
CCC TCG-3′.
2.4. Transduction of THP-1 cells
TheTHP-1 cells (1 × 106)were seeded in 6-cmPetri dishes in 500 μL
of complete medium, and transduced using the lentiviral vectors at a
multiplicity of infection of 3:1. Transductionwas performed in the pres-
ence of 8 μg/mL polybrene for 24 h. The cells were washed with RPMI-
1640 medium, and replated in RPMI-1640 with 10% FBS. Resistant
clones were selected using 2 μg/mL puromycin, and expanded. The
level of target gene expression was determined by western blotting.
2.5. In vitro proliferation assay
After serum starvation overnight, the THP-1 cells were pretreated
for 24 h with the NS 398, BQ 123, or BQ 788 inhibitor for 30 min or
the infected lentivirus carrying the scrambled, ET-1, or COX-2
shRNA, followed by treatment with 100 ng/mL VEGF-C for 24 h.
The proliferation rates were assessed using the MTS assay (Promega,
Madison,WI, USA). The absorbance at 490 nmwas recorded using an
MQX200 plate reader (Bio-Tek Instruments, Winooski, VT, USA). The
proliferation rates were also analyzed using the Cyto-ID Red Long-
term Cell Tracer Kit (Enzo Life Sciences, Farmingdale, NY, USA) ac-
cording to the manufacturer's instructions.
2.6. Chemotherapy and THP-1 survival
The THP-1/scrambled shRNA, the THP-1/ET-1 shRNA, and the THP-1/
COX-2 shRNA cells (8 × 103 cells/well) were pretreated with 100 ng/mL
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100 ng/mL VEGF-C and one of the chemotherapeutic agents,
etoposide or Ara-c, was added daily to the VEGF-C-pretreated cells
during a 48-h incubation. The cell survival rates were assessed
using the MTS assay. The THP-1/neo/scrambled shRNA, the THP-1/
VEGF-C/scrambled shRNA, the THP-1/VEGF-C/ET-1 shRNA, and the
THP-1/VEGF-C/COX-2 shRNA cells (8 × 103 cells/well) were treated
with the vehicle or a chemotherapeutic agent daily in serum-free
conditions for 48 h, and the cell survival rates were assessed using
the MTS assay.
2.7. Reverse-transcriptase polymerase chain reaction (RT-PCR) and real
time-PCR (QPCR)
ThemRNAwas isolated using the TRIzol reagent (Invitrogen), and
the RT reaction was performed as described [19]. The quantitative real
time-PCR (QPCR) analysis was performed using the SYBR Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA, USA) in an ABI Prism
7300 QPCR system (Applied Biosystems). The primer sequences used
for QPCR are listed in Supplementary Table 1.
2.8. Western blot analysis
Anti-COX-2 and anti-ET-1 antibodies were purchased from BD
Biosciences (San Jose, CA, USA) and GeneTex (Irvine, CA, USA), respec-
tively. Anti-cyclin A2 and anti-cyclin E2 antibodies were purchased
from Epitomic (Burlingame, CA, USA). Antibodies against CDK2, Bcl-2,
Bcl-XL, Bad, Bax, ET-1, and β-actin were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA), and antibodies against CDK4, CDK6,
p21 Cip1, p27 Kip1, p15 INK4B, p16 INK4A, and cyclin D3 were pur-
chased from Cell Signaling Technology (Danvers, MA, USA). Protein
lysates were prepared as previously described [19].Western blotting
was performed using primary antibodies speciﬁc for the following
proteins: COX-2, ET-1, CDK2, CDK4, CDK6, cyclin A2, cyclin D3, cyclin
E2, p15 INK4B, p16 INK4A, p21 Cip1, p27 Kip1, Bcl-2, Bcl-XL, Bad,
Bax, or β-actin.
2.9. Immunoprecipitation
The CDK2 protein was immunoprecipitated from lysates containing
800 μg of total protein using 2 μg of anti-CDK2 antibody and 20 μL
protein A/G agarose beads (Santa Cruz Biotechnology) as previously
described [20]. The precipitates were washed 5 times with lysis buffer,
and once with phosphate buffered saline (PBS). The precipitated pellet
was resuspended in sample buffer (50 mM Tris, pH 6.8; 100 mM
bromophenol blue; and 10% glycerol), and heated at 90 °C for 10 min
before electrophoresis to separate the CDK2 protein from the A/G aga-
rose beads.
2.10. Flow cytometry analysis
The THP-1/scrambled shRNA, the THP-1/ET-1 shRNA, and the
THP-1/COX-2 shRNA cell lines were grown in RPMI medium supple-
mented with 10% FBS. After the cells had reached subconﬂuence, they
were rendered quiescent, and challenged with vehicle or 100 ng/mL
VEGF-C for 24 h. The challenged cells were harvested, washed twice
with 0.1% dextrose in PBS, and ﬁxed with 70% ethanol at−20 °C. The
nuclear DNA was stained using 50 mg/mL PI and 2 U/mL DNase-free
RNase, and quantiﬁed using ﬂuorescence-activated cell sorter (FACS).
The proportion of nuclei in each phase of the cell cycle was determined
using the WinMDI 2.9 DNA analysis software.
2.11. Animals
Male, age-matched NOD/SCID-IL2Rγnull (NSG) mice (6- to 8-weeks-
old)were used as tumor xenograftmodels. All animalsweremaintainedin cages in a pathogen-free isolation facilitywith 12-h light/dark cycling.
Rodent chow and water were provided ad libitum. All animal experi-
ments were conducted in accordance with the guidelines of the Taipei
Medical University Animal Ethics Research Board.
2.12. Tumor growth assay
The NSG mice were injected subcutaneously in the right ﬂank
with 2 × 106 THP-1/neo/scrambled shRNA, THP-1/VEGF-C/scrambled
shRNA, THP-1/VEGF-C/ET-1 shRNA, or THP-1/VEGF-C/COX-2 shRNA
cells in 0.1 mL of RPMI 1640 medium. After transplantation, the
tumor size was measured using calipers, and the tumor volume
(mm3)was calculated as length × width2 × 1/2.When a tumor reached
180 mm3, intraperitoneal injections of vehicle (water) or Ara-C (0.5 or
1 mg/kg)were administered to themouse 5 times perweek. Theweight
of each mouse was recorded every 2 days to evaluate the side effects of
Ara-C administration, and the tumor size was measured. The mice
were sacriﬁced on day 11 following the last Ara-C or control injection.
Tumors were resected for immunohistochemical staining.
2.13. Immunohistochemical and immunocytochemical staining
Tumor tissues were parafﬁn-embedded, sectioned, and processed
for immunohistochemical staining, and the AML cell lines were
cytospinned on glass slides, ﬁxed, and processed for immunocyto-
chemical staining as previously described [21,22]. Immunoreactivity
was detected using the DAB Peroxidase Substrate Kit (Vector Labora-
tories, Burlingame, CA, USA), and specimens were counterstained
with hematoxylin (Merck, Darmstadt, Germany). A proliferation
index for the tissue sections was determined by Ki67 (Dako) immu-
nostaining, and Ki67-positive cells were counted at ×400 magniﬁca-
tion in 4 ﬁelds per THP-1 tumor section. The ET-1 expression level in
the cytospins was determined using an anti-human ET-1 antibody,
and non-immune goat IgG (Santa Cruz Biotechnology) was used as
a negative control.
2.14. Statistical analysis
The continuous variables are reported as the mean ± standard
error (SE). Statistical analyses were performed using the Statistical
Package for Social Science software, version 16 (SPSS, Chicago, IL,
USA).When data from 2 different groups were compared, a Student's
t-test was used. A one-way analysis of variance followed by a Tukey
post-hoc test was used when 3 or more groups were compared. Re-
sults of comparisons with a P value less than 0.05 for a 95% conﬁ-
dence interval were considered statistically signiﬁcant.
3. Results
3.1. VEGF-C induces ET-1 expression in leukemic cells
To identify which genes, in addition to COX-2, were co-regulated
by VEGF-C in AML cells, we performed a cDNAmicroarray analysis of
THP-1 cells, which is a low VEGF-C expressing AML cell line (Sup.
Fig. 1), treated with 100 ng/mL VEGF-C for 0 and 8 h. The expression
of several cell survival-, proliferation-, and angiogenesis-related genes
was altered after VEGF-C treatment for 8 h, compared with their ex-
pression proﬁles at 0 h of VEGF-C treatment (Sup. Table 2). After the
re-evaluation of these genes using semi-quantitative RT-PCR, we con-
ﬁrmed that the mRNA expression of BCL3, EDN1, and IL-1β was up-
regulated in a time-dependentmanner following the VEGF-C treatment
in amanner similar to that of COX-2 (PTGS2), and that the expression of
GATA6 was down-regulated following the VEGF-C treatment (Sup.
Fig. 2).
Endothelin-1 (ET-1) encoded by the EDN1 gene is a relevant growth
factor in several solid tumor types [23]. We ﬁrst examined the
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The THP-1 and HL-60 cell lines were incubated with 100 ng/mL
VEGF-C for intervals of 0 to 24 h. The mRNA levels of ET-1 increased,
reaching maximum expression after 2 h of VEGF-C treatment, and
declined subsequently in both cell lines (Fig. 1A). We also evaluated
the level of ET-1 protein expression induced by VEGF-C, and observed a
time-dependent induction pattern in both cell lines (Fig. 1B). To further
conﬁrm the induction of ET-1 protein expression by VEGF-C, we per-
formed immunocytochemical staining of ET-1 in THP-1 and HL-60
cells. The results showed an increase in ET-1 protein expression in
these cells after treatment with VEGF-C for 8 h (Fig. 1C). Similar in-
creases in ET-1 mRNA and protein expression following VEGF-C treat-
ment were also observed in U937 cells (Sup. Fig. 3). These results
suggest that ET-1 is a downstream target that is regulated by VEGF-C-
mediated signaling in AML cells.
3.2. ET-1 is involved in VEGF-C-mediated upregulation of COX-2 expression
in leukemic cells
Recent studies have demonstrated that the ET-1-signaling axis
regulates COX-2 expression in endothelial, epithelial, and various
solid tumor cells [24–27]. To determinewhether ET-1 induction is in-
volved in the signal transduction pathway leading to VEGF-C-mediated
COX-2 expression, experiments were performed using the endothelin
receptor A (ETRA) antagonist, BQ 123, or the endothelin receptor B
(ETRB) antagonist, BQ 788. Pretreatment of the cells for 30 min with
10 μMBQ 123 signiﬁcantly attenuated the VEGF-C-mediated upregula-
tion of COX-2 expression, but treatment with BQ 788 had no signiﬁcant
inhibitory effect (Fig. 2A). To further evaluate the role of ET-1 in theFig. 1. VEGF-C induces ET-1 expression in acute myeloid leukemia cells. (A and B) Treatment o
duced ET-1mRNA (A) and protein (B) expressions in a time-dependentmanner, peaking at 1 h
cells were subjected to serum starvation for 24 h, and treated with 100 ng/mL VEGF-C. Cells w
using QPCR and western blotting, respectively. The ET-1 mRNA and protein levels were normal
mean ± SE (n = 3). *P b 0.05, compared to the vehicle. (C) The THP-1 and HL 60 cells were se
by immunocytochemical staining using an anti-ET-1 antibody. Normal goat IgG was used as thVEGF-C-mediated regulation of COX-2 expression, a stably transfected
ET-1 knockdown strain of THP-1 cells was established based on lentivi-
rus expression of ET-1 speciﬁc shRNAs. These cells expressed lower
levels of ET-1, even in the presence of VEGF-C, compared with THP-1
control cells expressing the scrambled shRNA (Sup. Fig. 4A). The
blockade of ET-1 expression by shRNA-mediated gene knockdown
signiﬁcantly prevented the VEGF-C-mediated upregulation of COX-2
expression (Fig. 2B). Furthermore, although THP-1 cells express
low levels of VEGF-C, ET-1 and COX-2, depletions of endogenous
VEGF-C or ET-1 still result in down-regulations of COX-2 expression
(Sup. Fig. 4B and C). To further establish a direct linkage between ET-
1 and COX-2 expressions, THP-1 cells were treated with 100 nM of
recombinant ET-1 protein at different intervals, and COX-2 mRNA
and protein levels were quantiﬁed. Fig. 2C shows that COX-2 mRNA
expression peaked at 4 h after ET-1 treatment, and declined to normal
levels at 24 h after ET-1 treatment. The expression of COX-2 protein
also increased in a time-dependent manner following ET-1 treatment
(Fig. 2D). Collectively, our results suggest that the ET-1/ETRA axis regu-
lates the VEGF-C-mediated stimulation of COX-2 expression in AML
cells.
3.3. Role of ET-1 and COX-2 in VEGF-C-induced proliferation in leukemic
cells
Because VEGF-C has been shown to stimulate leukemia cell prolifer-
ation [10], we examined whether ET-1 and COX-2 participated in the
regulation of the proliferative effects of VEGF-C in leukemia cells.
According to the results of the MTS assays, the proliferation of THP-1
cells was elevated after VEGF-C treatment. The stimulation of THP-1f human acute myeloid leukemic cell lines, THP-1 and HL-60, with 100 ng/mL VEGF-C in-
inmRNA expression and 12 h in protein expression in both cell lines. The THP-1 andHL-60
ere harvested at the indicated time points. Total RNA and protein extracts were analyzed
ized based on GAPDHmRNA and β-actin protein levels, respectively. Values represent the
rum starved, and treatedwith VEGF-C for 8 h. The expression of ET-1 protein was detected
e non-speciﬁc staining control. Bar = 200 μM.
Fig. 2.ET-1 is essential for VEGF-C-upregulated COX-2 expression inTHP-1 cells. (A) TheVEGF-C-induced upregulation of COX-2 expression in THP-1 cellswas abolishedby treatmentwith
10 μMBQ123, an ETRA antagonist, but not by treatment with 10 μMBQ788, an ETRB antagonist. THP-1 cells were serum starved for 24 h, and treatedwith BQ 123 or BQ 788 for 30 min,
followedbyVEGF-C treatment for 24 h. The cellswere harvested, and cell extractswere analyzedbywestern blotting. TheCOX-2 protein level normalized to that of the β-actin protein. (B)
THP-1 cells expressing ET-1 shRNAs (THP-1/ET-1 shRNA) or scrambled shRNA (THP-1/scrambled shRNA) were serum starved, and treated with 100 ng/mL VEGF-C for 24 h. The level of
COX-2 protein expressions was normalized to that of the β-actin protein. (C and D) Treatment with 100 nM recombinant ET-1 induced COX-2 mRNA (C) and protein (D) expressions in
THP-1 cells in a time-dependent manner, peaking at 4 h in mRNA and protein expressions. Serum starved THP-1 cells were treated with recombinant ET-1 protein, and harvested at the
indicated time points. The COX-2mRNA and protein extracts were examined as described in Fig. 1. Values represent themean ± SE (n = 3). *P b 0.05 comparedwith the VEGF-C (A and
B) or vehicle (C and D) treatment group.
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trations of BQ 123, but was not signiﬁcantly affected by pretreatment
with BQ 788 (Fig. 3A). In addition, treatment with NS-398 suppressed
the proliferative effects of VEGF-C in a concentration-dependent
manner (Fig. 3A). To further evaluate the roles of ET-1 and COX-2
in VEGF-C-mediated proliferative effects in AML cells, a stably
transfected COX-2 knockdown strain of THP-1 cells was established.
The level of COX-2 protein expression in the COX-2 knockdown
strain was compared using western blotting to that in THP-1 cells
transfected with the scrambled shRNA (Sup. Fig. 4D). According to
the results of the MTS assays, the proliferation rate induced by
VEGF-C was signiﬁcantly lower in ET-1 and COX-2 knockdownstrains (THP-1/ET-1 shRNA and THP-1/COX-2 shRNA) than in the
control cells (THP-1/scrambled shRNA; Fig. 3B).
We also used a long-term cell tracer assay, which demonstrates cell
proliferation based on a loss of ﬂuorescence intensity in a sample, to de-
tect cell proliferation in both ET-1 and COX-2 knockdown strains fol-
lowing VEGF-C treatment. The baseline ﬂuorescence intensities (0 h)
for the knockdown strains and the control cells were similar. Both ET-
1 and the COX-2 knockdown strains retained their ﬂuorescence intensi-
ty after VEGF-C treatment for 48 h, whereas the ﬂuorescence intensity
of the control cells decreased following VEGF-C treatment (Fig. 3C).
These data suggest that ET-1 and COX-2 both play essential roles in
the VEGF-C-mediated stimulation of cell proliferation in leukemia cells.
Fig. 3. ET-1 and COX-2 are essential for VEGF-C-induced proliferation in THP-1 cells. (A) VEGF-C-induced proliferation of THP-1 cells was concentration-dependently abolished by ETRA
antagonist, BQ123 (5 and 10 μM) andCOX-2 inhibitor, NS 398 (1–30 μM), but not by the ETRB antagonist, BQ788 (5 and 10 μM). Serum starved THP-1 cellswere pretreatedwith different
concentrations of NS 398, BQ123, or BQ788 for 30 min, followed byVEGF-C treatment for 24 h. The proliferation rates of THP-1 cellswere analyzed using anMTS assay. (B) The THP-1/ET-
1 shRNAs, THP-1/COX-2 shRNAs, or THP-1/scrambled shRNA cell lines were serum starved, and treated with 100 ng/mL VEGF-C for 24 h. The proliferation rates of THP-1 cells were an-
alyzed using an MTS assay. (C) The Cyto-ID Red Long-Term Cell Tracer Kit was used to detect cell proliferations. The THP-1/ET-1 shRNAs, THP-1/COX-2 shRNAs, and THP-1/scrambled
shRNA cell lines were labeled with a long-term cell tracer, followed by treatment with or without 100 ng/mL VEGF-C for 48 h. The ﬂuorescence intensities of the various cell lines
were examined using FACS. The ﬂuorescence of the cell tracer decreases as cells proliferate. Cells with lower ﬂuorescence intensity at 48 h, compared with 0 h, were considered to rep-
resent a proliferating population. Values represent the mean ± SE (n = 3). *P b 0.05, compared with the VEGF-C treatment group.
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activity
To deﬁnitively demonstrate the effects of VEGF-C on a speciﬁc phase
of the cell cycle and the roles of ET-1 and COX-2 in VEGF-C-mediated
regulation of the cell cycle in AML cells, we examined cell-cycle progres-
sion in THP-1/ET-1 shRNA, THP-1/COX-2 shRNA, and THP-1/scrambled
shRNA cell lines following VEGF-C treatment. The proportion of S phase
cells increased after VEGF-C treatment in the THP-1/scrambled shRNA
cells, whereas the proportion of G0/G1 phase cells decreased. In
contrast, S phase accumulation was blocked in both ET-1 and COX-2
knockdown strains following VEGF-C treatment (Fig. 4A), and no signif-
icant change in S phase accumulation occurred in the THP-1/ET-1
shRNA, THP-1/COX-2 shRNA, and THP-1/scrambled shRNA cell lines
after treatment with 10% FBS (Sup. Fig. 5), suggesting that ET-1 and
COX-2 play critical roles in the VEGF-C-mediated cell-cycle progression
in leukemia cells.
To further investigate themolecularmechanisms bywhich ET-1 and
COX-2 function in the VEGF-C-mediated cell cycle progression, we
examined the expression of G1/S cyclins in the THP-1/ET-1 shRNA,
THP-1/COX-2 shRNA, and THP-1/scrambled shRNA cell lines following
VEGF-C treatment. Cyclin E2 protein expression signiﬁcantly increased
in the THP-1/scrambled shRNA cells after treatment with VEGF-C for24 h, but it did not increase in either the ET-1 or the COX-2 knockdown
strains under the same conditions (Fig. 4B). We also examined the ex-
pression of cyclin-dependent kinases (CDKs) after treatment with
VEGF-C. The expression of CDK2 protein, which forms a complex with
cyclin E tomediate the G1/S transition, signiﬁcantly increased following
treatment with VEGF-C for 24 h, but it did not increase in either the ET-
1 or the COX-2 knockdown strains under the same conditions (Fig. 4C).
Because CDK activity can be reduced by a group of cyclin-dependent
kinase inhibitors (CKIs), we examined the levels of various CKI proteins
in the VEGF-C-treated THP-1 cells. The level of p27Kip1 protein, a cyclin
E/CDK2 inhibitor, decreased following treatment with VEGF-C, and was
rescued by ET-1 or COX-2 gene knockdown. However, the expression
of p21 Cip1, another cyclin E/CDK2 inhibitor, and p15 INK4B and p16
INK4A, both CDK4 inhibitors, was not altered following treatment
with VEGF-C or by the depletion of ET-1 or COX-2 (Fig. 4D). A similar
rescue effect on the VEGF-C-mediated increase in cyclin E2/CDK2 ex-
pression and the concurrent reduction in p27 Kip1 expression was
also observed in THP-1 cells pretreated with BQ 123 and NS-398
(Fig. 4E).
The CKIs exert their inhibitory effects on cyclin-dependent kinases
by binding to the cyclin-CDK complex. Thus, we performed immuno-
precipitation assays to examine the effect of VEGF-C on the formation
of CDK2–p27 Kip1 complex in the THP-1/ET-1 shRNA, THP-1/COX-2
Fig. 4. The role of ET-1 and COX-2 in VEGF-C-regulated changes in cell-cycle activity. (A) The THP-1/scrambled shRNA, THP-1/shCOX-2, and THP-1/shET-1 cell lines were released from
quiescence following treatment with VEGF-C or vehicle for 24 h. The changes in the DNA content of cells were determined by FACS. The percentage of cells at the G0/G1, S, or G2/M phase
of the cell cycle was determined using the WinMDI 2.9 DNA analysis software. The results shown are from one representative experiment. Three independent experiments were per-
formed that showed similar patterns. (B–D) The THP-1/scrambled shRNA, THP-1/shCOX-2, and THP-1/shET-1 cell lines were serum starved for 24 h, and treated with 100 ng/mL
VEGF-C for another 24 h. The cells were harvested, and subjected to western blot analysis to detect the expression of (B) cyclins, (C) CDKs, and (D) CKIs. (E) Serum starved THP-1 cells
were treated with 10 μM BQ 123 or 10 μMNS 398 for 30 min, followed by treatment with 100 ng/mL VEGF-C for 24 h. Cells were harvested, and subjected to western blotting to detect
the expression of the cyclin E2, CDK-2, and p27 Kip1. The cyclin E2, CDK-2, and CKI protein levels were normalized to that of β-actin. Values represent the mean ± SE (n = 3). *, $,
#P b 0.05, compared with the VEGF-C treatment group. (F) The shRNA-mediated gene knockdown of ET-1 or COX-2 expression abolished the VEGF-C-mediated suppression of CDK2
and p27 association in THP-1 cells. The CDK2 protein was immunoprecipitated using an anti-CDK2 antibody, and the CDK2–p27 Kip1 complex was detected using an anti-p27 Kip1
antibody.
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CDK2–p27 Kip1 complex formation decreased in cells treated with
VEGF-C, and this suppressive effect was abolished by either ET-1 or
COX-2 gene knockdown. Collectively, these ﬁndings suggest that the
VEGF-C/ET-1/ETRA/COX-2 axis induces leukemia cell proliferation by
increasing cyclin E2/CDK2 expression and inhibiting p27 Kip1 expres-
sion and CDK2–p27 Kip1 complex formation, which together promote
the G1/S cell-cycle transition.
3.5. Role of ET-1 and COX-2 in VEGF-C-induced chemoresistance of THP-1
cells in vitro
Previous studies have reported that higher levels of endogenous
VEGF-C decreased chemotherapy drug responsiveness in AML cells
[17]. Similarly, we observed that VEGF-C-treated THP-1 cells wereresistant to the cytotoxic effects of etoposide and Ara-C (Fig. 5A, left
panel). However, in the ET-1 and COX-2 knockdown strains of THP-1,
the protective effect of VEGF-C against etoposide and Ara-C was atten-
uated (Fig. 5A, middle and right panels). We next established THP-1
cells stably expressed VEGF-C alone or coexpressed with ET-1 shRNA
or COX-2 shRNA (Fig. 5B). Similar protection and protection suppres-
sive effects of VEGF-C and ET-1/COX-2 shRNAs, respectively can be ob-
served in these stable cells (Fig. 5C).
The expression of members of the Bcl-2 gene family has also been
reported to be involved in VEGF-C-mediated chemoresistance [10].
In our experiments, the expression of the Bcl-2 protein increased
after VEGF-C treatment, whereas the expression of Bcl-xl, Bad, and
Bax was not signiﬁcantly altered (Fig. 5D). Thus, treatment with
VEGF-C resulted in the elevation of the Bcl-2/Bax ratio, which is an
important index for anti-apoptosis activity in cells [28]. Consistent
Fig. 5. ET-1 and COX-2 are essential for VEGF-C-induced chemoresistance in THP-1 cells in vitro. (A) The THP-1/scrambled shRNA, THP-1/shCOX-2, and THP-1/shET-1 cell lines were ex-
posed to Ara-C or etoposide for 24 h. The respective inhibition of cell survival was determined using anMTS assay. In some conditions, cells were pretreated with 100 ng/mL VEGF-C for
24 h before the chemotherapeutic agentswere added, and the VEGF-Cwas also added to the cultures daily. (B and C) The THP-1/scrambled shRNA, THP-1/shCOX-2, and THP-1/shET-1 cell
lines were infected with lentivirus carrying the VEGF-C or control vector (B), and were then treated with Ara-C or etoposide for 24 h. The respective inhibition of cell survival was deter-
mined by MTS assay (C). Values represent the mean ± SE (n = 3). Results were analyzed using a one-way analysis of variance with a Tukey post hoc test and 95% conﬁdence interval.
Different letters represent different levels of signiﬁcance. (D) The expression of Bcl-2 family proteins in scrambled shRNA, ET-1 shRNA, and COX-2 shRNA stably transfected THP-1 cell
lines following treatment with 100 ng/mL VEGF-C for 24 h was examined using western blotting. The Bcl-2/Bax ratios were quantiﬁed by densitometry (right panel).
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following VEGF-C treatment was suppressed in both ET-1 and COX-2
knockdown strains of THP-1 (Fig. 5D). Similarly, pretreatment of THP-
1 cells with BQ 123 or NS-398 also suppressed the increase of the Bcl-
2/Bax ratio following VEGF-C treatment in concentration-dependent
manner (Sup. Fig. 6).3.6. Role of ET-1 and COX-2 in VEGF-C-induced chemoresistance of THP-1
cells in vivo
Following our investigation of VEGF-C-mediated chemoresistance
in vitro, we examined the role of ET-1 and COX-2 in VEGF-C-mediated
chemoresistance in vivo. We established a mouse xenograft tumor
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shRNA, or THP-1/VEGF-C/COX-2 shRNA cells into NSG mice. Treatment
with Ara-C was initiated when the tumors reached approximately
180 mm3, and the THP-1 xenografted mice were treated 5 times per
week with 1 mg/kg Ara-C or vehicle. On 11 days after Ara-C treatment,
the THP-1/VEGF-C xenografts exhibited greater chemoresistant activity,
compared to that of the wild type THP-1 (THP-1/neo) xenografts.
The VEGF-C-induced chemoresistance was signiﬁcantly reduced by
co-expression of the ET-1 or COX-2 shRNAs, as evidenced by reduced
tumor volume (Fig. 6A) and tumor weight (Fig. 6B). No signiﬁcant
difference in body weight was observed among these groups (Fig. 6C).
We also examined the expression of the cell proliferation marker,
Ki67, by immunocytochemical staining to evaluate the response of
the xenografted tumor cells. The mean number of Ki67 positive
tumor cells after Ara-C treatment was signiﬁcantly reduced, com-
pared with the wild type THP-1 (THP-1/neo) xenografts (Fig. 6D).
In contrast, there was no signiﬁcant difference in the proportion of
Ki67-positive cells between the Ara-c-treated THP-1/VEGF-C tumor
cells and vehicle-treated THP-1/neo tumor cells. The knockdown of
ET-1 or COX-2 expression resulted in increased chemo-sensitivity, as
evidenced by lower number of Ki67-positive cells in the Arac-treated
THP-1/VEGF-C/ET-1 shRNA and THP-1/VEGF-C/COX-2 shRNA tumor
cells than Ara-c treated THP-1/VEGF-C tumor cells (Fig. 6D). Similar
chemoresistance and chemoresistance attenuate effects of VEGF-C and
ET-1/COX-2 shRNAs, respectively can be observed in mice treated
with 0.5 mg/kg Ara-C (Sup. Fig. 7). Collectively, these results suggest
that ET-1 signaling and COX-2 signaling are crucial to VEGF-C-mediated
chemoresistance in vivo.Fig. 6. ET-1 and COX-2 are essential for VEGF-C-induced chemoresistance in THP-1 cells in vivo.
VEGF-C/ET-1 shRNA, or THP-1/VEGF-C/COX-2 shRNA cell lines subcutaneously in the leftﬂank o
1/neo, THP-1/VEGF-C, THP-1/VEGF-C/ET-1 shRNA, and THP-1/VEGF-C/COX-2 shRNA recipients
week. Eleven days after Ara-C treatment, the animals were sacriﬁced, and tumor specimens w
withwater or Ara-C for 11 days. Scale bar = 1 cm. Lower panel: average tumor volume of each
(n = 8). Results were analyzed using a one-way analysis of variance (ANOVA) with a Tukey po
niﬁcance. (C) The change in body weight (g) during the experiment is shown. (D) A prolifera
counted at ×400 magniﬁcation in 4 ﬁelds per THP-1 tumor section. Hematoxylin and eosin-
(n = 8). Results were analyzed using a one-way ANOVA with a Tukey post hoc test and 95% c4. Discussion
The importance of angiogenesis and angiogenic factors has been
well characterized in solid tumors. Recently, abnormal bone marrow
angiogenesis has been reported in hematologic malignancies. A variety
of angiogenic factors, such as VEGF-A, VEGF-C, angiopoietin-1 and -2,
FGF, HGF, and TGF-β, have been shown to be secreted by leukemic
cells [1,29]. In addition to modulating neovascularization, angiogenic
factors also participate in the regulation of pro-survival processes in
leukemia cells, but the precisemechanism involved still needs to be elu-
cidated further.
In our current study, we demonstrated that VEGF-C may promote
leukemia cell proliferation and chemoresistance by inducing COX-2
expression through an ET-1/ETRA-dependent signaling pathway.
The COX-2 activation results in the formation of the cyclin E/CDK2
complex, and suppresses the expression of the cyclin E/CDK2 inhib-
itor, p27 Kip1, facilitating S phase entry. In addition, the activation
of the VEGF-C/ET-1/ETRA/COX-2 signaling axis induces Bcl-2 expres-
sion, and desensitizes leukemia cells to chemotherapy drugs. These
ﬁndings highlight the importance of the VEGF-C/ET-1/ETRA/COX-2 sig-
naling axis in the proliferation and chemoresistance of leukemia cells.
The ET-1 protein is an important vasoactive mediator that plays
roles in inﬂammation, vascular remodeling, and angiogenesis. Re-
cently, the dysregulation of the ET axis was implicated in the devel-
opment of various solid cancers [30–32]. However, the expression
proﬁle and cellular function of ET-1 in tumors of hematopoietic origin re-
main largely unknown. Mathieu et al. reported the expression of ET-1 in
human megakaryoblastic leukemia cell lines and normal bone marrowXenografted THP-1 tumorswere generated by injecting THP-1/neo, THP-1/VEGF-C, THP-1/
fmaleNSGmice.When the tumors reached approximately 180 mm3, 1 mg/kgAra-C (THP-
) or water (THP-1/neo recipients) was intraperitoneally administered to mice 5 times per
ere collected. (A) Upper panel: gross appearance of subcutaneous tumors after treatment
group is shown. (B) Final tumorweightswere compared. Values represent themean ± SE
st hoc tests and 95% conﬁdence interval. Different letters represent different levels of sig-
tion index was determined based on Ki67 immunostaining, and Ki67-positive cells were
stained sections revealed the histological morphology. Values represent the mean ± SE
onﬁdence interval. Different letters represent different levels of signiﬁcance.
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ET-1 expression in VEGF-C-activated AML cell lines, which represents as
a crucial downstream effector of VEGF-C signaling for the regulation of
COX-2 expression.
We previously reported that VEGF-C induced COX-2 expression
through JNK activation and AP-1 nuclear translocation, resulting in
the binding of AP-1 to the cyclic adenosine 3′,5′-monophosphate re-
sponse element (CRE) in the COX-2 promoter [13]. In our current
study, we identiﬁed ET-1 as another key mediator of VEGF-C-induced
COX-2 expression. In addition, ET-1 has been shown to regulate CRE-
dependent remodeling genes, including COX-2, in pulmonary vascular
smooth muscle cells [34], and ET-1 also activates MAPK/AP-1 signaling,
which upregulates COX-2 and MMP-9 expressions in chondrosarcoma
cells and brain astrocytes, respectively [35,36]. In this regard, VEGF-C/
VEGFR-3 might also activate JNK/AP-1 signaling through an ET-1-
dependent mechanism in addition to directly activating MAPK through
the recruitment of the C10 kinase regulator (CRK) I/II in AML cells [37].
Alternatively, the AP-1 binding site in the ET-1 promoter has long
been recognized as an important response element in the regulation
of ET-1 [38]. The recruitment of AP-1 to the ET-1 promoter is essential
for hypoxia-, TGF-β-, leptin-, thrombin-, and insulin-induced ET-1
expressions [38]. The VEGF-C/VEGFR-3 axis might also induce ET-1
expression through MAPK/AP-1 activation. Although further studies
arewarranted to elucidate the interplay of VEGF-C, ET-1, andMAPK sig-
naling, our data indicate an essential role for ET-1 in VEGF-C-mediated
COX-2 expression and leukemia proliferation and chemoresistance.
A previous study showed that ET-1-mediated signal transduction
activates the transmembrane G protein-coupled receptors (GPCRs),
ETRA, and ETRB [39], and that the ET-1 protein bound to both recep-
tors with equal afﬁnity [40]. However, although ET-1 binding to
ETRA activates a signaling network that is involved in the develop-
ment and progression of cancer, including cell proliferation, apopto-
sis, cell invasion, metastasis, and angiogenesis [41], the ET-1 binding
of ETRB has been shown to affect processes that inhibit cancer, inducing
apoptosis and promoting ET-1 clearance [42]. Changes in the relative ra-
tios of ETRA to ETRB can stimulate the progression of cells from a nor-
mal phenotype to a malignant phenotype [43]. Accordingly, our
examination of the effects of the ET-1 receptor antagonist revealed
that ETRA is the essential GPCR involved in the VEGF-C-mediated up-
regulation of COX-2 expression. In addition, the ETRB gene is often
hypermethylated, leading to reduced or absent receptor expression
in cancer tissues [44,45]. Methylation of the ETRB promoter has
also been reported in patients with different types of leukemia, in-
cluding AML [46]. Although the participation of ETRB in cancer ma-
lignance and COX-2 expression was also reported [35,36,47], our
results together with previous reports support the dominant charac-
ter of ETRA in ET-1 signaling and tumor progression of AML cells.
Known primarily for its ability to promote the formation of new
lymphatic vessels by inducing proliferation, migration, and sprout
formation of existing lymphatic endothelial cells [2–5], VEGF-C has
also been implicated in the progression of a diverse range of cancer
types through an autocrine mechanism [48]. High-level VEGF-C ex-
pression has been shown to be a predictor of poor prognosis in
AML, in which resistance to chemotherapy is predominant [16]. The re-
sults of in vitro studies suggest that the VEGF-C/VEGFR-3 axis mediates
chemoresistance in AML cells by upregulating Bcl-2 expression [10], an
important resistancemechanism against chemotherapy drugs in leuke-
mia cells [49].
Our current ﬁndings suggest that ET-1-induced COX-2 expression
is crucial in the VEGF-C/VEGFR-3 axis-mediated upregulation of Bcl-2
expression. The inhibition of COX-2 activity or ET-1/ETRA signaling
either by gene knockdown using speciﬁc shRNAs or by treatment with
chemical inhibitors suppresses VEGF-C-mediated upregulation of
Bcl-2 expression. Furthermore, the knockdown of ET-1 or COX-2 ex-
pression reduced VEGF-C-mediated chemoresistance against Ara-C
treatment in vivo. Although COX-2 expression and prostaglandin E2production have been reported to provide chemoresistant beneﬁts
in a variety of cancer cells [50], our current study provides the ﬁrst
evidence-based proposal of VEGF-C/ET-1/ETRA/COX-2/Bcl-2-medi-
ated signaling in chemoresistance in AML cells.
COX-2-mediated inductions of VEGF-C expression were reported in
multiple types of cancer tissues and involved in tumor progression
and metastasis [51–53]. Activation of prostaglandin E (EP) receptors
through PGE2 production by COX-2 was found to mediate VEGF-C ex-
pression [52,53]. Therefore, it is highly possible that VEGF-C-induced
COX-2 expression can in turn regulate VEGF-C expression and thus con-
stitute a closed positive up-regulatory loop. Further investigations are
required to understand whether this feedback activation loop exists in
AML cells andwhether it plays important roles in the crosstalk between
AML cells and stromal cells.
Our previous data demonstrated that the pathogenic role of VEGF-C
in leukemia is the result of the upregulation of COX-2 expression and
subsequent stimulation of angiogenesis [13]. In this study, we also dem-
onstrated that VEGF-C may contribute to cell proliferation and
chemoresistance through an ET-1-dependent induction of COX-2 ex-
pression. Thus, VEGF-C- and COX-2-mediated signaling may promote
tumor progression in multiple aspects, which strongly indicate that
the VEGF-C/ET-1/ETRA/COX-2 axis represents important potential ther-
apeutic targets for the treatment of AML.
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